Azitra, Inc. (NYSEAM: AZTR)
Health Care · Biotechnology · US
$0.16
+16.65% today · -85.6% 1Y
Azitra, Inc. (NYSEAM: AZTR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.26M and employs 13 people.
Over the last twelve months the share price has lost 85.6%, trading between 0.10 and 1.40.
Tweenvest scores Azitra, Inc. across four factors: quality 28/100. Its strongest factor is quality.
AZTR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.26M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.99
- Dividend yield
- —
- Beta (5Y)
- -1.18
- 52-week high
- $1.40
- 52-week low
- $0.10
- Avg volume (3M)
- —
- Shares outstanding
- 16.19M
- Employees
- 13
- Next earnings
- —
About Azitra, Inc.
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
- ISIN
- US05479L3024
- Founded
- 2014
- Listed since
- Jun 20, 2023
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.